Pharmaceuticals
YolTech Therapeutics to Initiate a Clinical Trial for YOLT-204, a First-in-Class Bone Marrow-Targeted In Vivo Gene Editing Therapy for β-Thalassemia
SHANGHAI, Jan. 20, 2025 /PRNewswire/ -- YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the initiation of a clinical trial forYOLT-204, an investigational therapy for the treatment of transfusion-dependent beta-thalassemia (TDT). TDT i...
2025-01-21 10:34
3421
Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
SHANGHAI, Jan. 16, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib Capsules (派舒宁®）has received marketing authorizatio...
2025-01-17 10:56
3382
LOTTE BIOLOGICS to Present at the 2025 J.P. Morgan Healthcare Conference
* New CEO James Park Delivers First Presentation at J.P. Morgan Healthcare Conference on "Advancing as a Global CDMO Leader" * Unveiling of Next-Generation ADC Platform 'SoluFlex Link': Enabling High-Potency, High-Yield ADC Development and Manufacturing * Incheon Songdo Bio Campus Plant 1 Un...
2025-01-17 07:11
6777
Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering
NEW YORK, Jan. 16, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company") (NASDAQ: HKPD), a leading provider of over the counter ("OTC") pharmaceutical cross-border e-commerce supply chain services inHong Kong, today announced the closing o...
2025-01-17 03:10
4589
(Taiwan) CMU Healthcare System and Nobel Laureate Randy Schekman Drive New Frontiers in Exosome Technology
TAICHUNG, Jan. 15, 2025 /PRNewswire/ -- On November 2, 2024, China Medical University (CMU) and Healthcare System hosted the International Forum of Extracellular Vesicles Technology and Novel Therapeutics to highlightTaiwan's advancements and explore new horizons in biomedical applications.Profes...
2025-01-16 09:00
3815
Celltrion unveils strategic vision for advancing its innovative drug pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
* Celltrion unveils strategic roadmap for the first time outlining its innovative drug development strategy and its plan to submit 13 Investigational New Drug (IND) application by 2028 * Company reinforces its commitment to a two-pillar growth strategy focusing on its groundbreaking new drug ...
2025-01-15 10:52
3305
Hong Kong Pharma Digital Technology Holdings Limited Announces Pricing of Initial Public Offering
NEW YORK, Jan. 14, 2025 /PRNewswire/ -- Hong Kong Pharma Digital Technology Holdings Limited ("Hong Kong Pharma" or the "Company"), a leading provider of OTC pharmaceutical cross-border e-commerce supply chain services inHong Kong, today announced the pricing of its initial public offering (the "...
2025-01-15 02:01
2483
ImmunoForge Receives IND Approval for Phase 2 Clinical Trial of 'Pemziviptadil' for DMD Cardiomyopathy Treatment from FDA, and KF1601, a chronic myeloid leukemia treatment, phase 1 clinical trial IND approved by MFDS
SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil (development code name PF1804),' a treatment for DMD (Duchenne Muscular Dystrophy) cardiomyopathy, from the U.S. Food and Drug Administration...
2025-01-14 21:00
3806
Simcere Zaiming and AbbVie Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
SHANGHAI and NORTH CHICAGO, Ill., Jan. 13, 2025 /PRNewswire/ -- Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096) and AbbVie Inc. (NYSE: ABBV) today announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500 is currentl...
2025-01-13 22:05
5214
CARsgen's Allogeneic CD19/CD20 CAR-T Therapy Administers First Dose in an Investigator-Initiated Trial
SHANGHAI, Jan. 13, 2025 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that KJ-C2219, an allogeneic CAR T-cell therapy targeting CD19/CD20, ...
2025-01-13 21:50
2535
WuXi AppTec Joins the Pharmaceutical Supply Chain Initiative (PSCI)
SHANGHAI, Jan. 12, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life sciences industries, announced that it has joined the Pharmaceutical Supply Chain Initiative (PSCI) as a Suppl...
2025-01-13 08:00
3659
Regor Releases Phase 2a Topline Results for RGT-075, an Oral Once-daily Small Molecule GLP-1R Agonist, and Begins Phase 2b Study in the US for the Treatment of Obesity
* Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau * No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo * Enrollment o...
2025-01-11 01:30
3775
Menarini Group and Insilico Medicine Enter a Second Exclusive Global License Agreement for an AI Discovered Preclinical Asset Targeting High Unmet Needs in Oncology
* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discovered through their generative AI platform, similar to the preclinical stage KAT6 inhibitor (MEN2312) licensed a year ago and which advanced rapidly into the clinical phase. * Under the agreement, M...
2025-01-10 22:00
3293
Harbour BioMed Announces License Agreement with Windward Bio for HBM9378/SKB378, an Anti-TSLP Fully Human Antibody for Immunological Diseases
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Jan. 10, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncology and immuno...
2025-01-10 21:01
5573
Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio
HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing and collaboration agreement for the global development and commercializa...
2025-01-10 15:00
3587
SN BioScience Propels SNB-101 to Phase 2 with IND Clearance from FDA
SEOUL, South Korea, Jan. 10, 2025 /PRNewswire/ -- SN BioScience today announced that its lead asset SNB-101 has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for a Phase1b/2 clinical trial. This achievement follows the designation of SNB-101 as...
2025-01-10 14:40
3503
In 2024, Complete Genomics expanded U.S. manufacturing and technology capabilities toward a diversified, reliable supply chain for its flexible and cost-effective NGS solutions
SAN JOSE, Calif., Jan. 9, 2025 /PRNewswire/ -- In 2024, Complete Genomics, a pioneering genomic sequencing company, expanded its U.S. manufacturing footprint with augmented technology capabilities to diversify its supply chain helping it to continue reliably serving customers with flexible, cost-...
2025-01-10 01:43
3406
Hengdian Group Capital and Apeloa Pharmaceutical to participate in 2025 J.P. Morgan Healthcare Conference
HANGZHOU, China, Jan. 9, 2025 /PRNewswire/ -- Hengdian Group Capital (HgC) and Apeloa Pharmaceutical (subsidiaries of Hengdian Group) will attend the 43rd Annual J.P. Morgan Healthcare Conference inSan Francisco from January 13-16, 2025. HgC CEO Gary Xu and Apeloa VP George Cai will be present a...
2025-01-09 22:00
3098
RiDYMO® Designs Cyclic Peptide for "Undruggable" β-Catenin Target Within Two Months
BEIJING, Jan. 8, 2025 /PRNewswire/ -- In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically "undruggable" protein, in just two months. This innovative AI-driven approach combines advanced algorithms, ...
2025-01-09 12:35
2946
Samsung Biologics extends collaboration with LigaChem Biosciences for ADC development
* Samsung Biologics to offer ADC services at new dedicated facility * Extended collaboration reflects successful partnership and expertise INCHEON,South Korea, Jan. 8, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO),...
2025-01-09 08:57
2962
Week's Top Stories
Most Reposted
Agoda Begins Limited Public Beta of New AI Assistant That Turns Travel Ideas into Bookable Trips
[Picked up by 288 media titles]
2026-09-15 11:00
Sovereign Investment Institutions Launch China-ASEAN Joint Investment Council
[Picked up by 267 media titles]
2026-09-16 09:09
Novo Holdings invests in ForYou Medical to support global growth in advanced wound care manufacturing
[Picked up by 264 media titles]
2026-09-10 15:00CLP Power Hosts AESIEAP CEO Conference 2026 in Hong Kong
[Picked up by 260 media titles]
2026-09-15 19:07
New ASEAN Study Reveals Businesses Are Rethinking Hiring and Investment as Growth Priorities Shift
[Picked up by 260 media titles]
2026-09-10 07:45
Most Read
ALLSWIFIT Introduces ActiveRise+, a Stable Carbon-Plate Running Shoe Built to Help Everyday Runners Train Smarter and Run Stronger
2026-09-11 21:00
13068
Cheetah Mobile Announces Second Quarter 2026 Unaudited Consolidated Financial Results
2026-09-11 10:36
8788